博瑞医药(688166) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥269,313,828.94, representing a 30.01% increase compared to the same period last year[6] - Net profit attributable to shareholders was ¥70,004,732.06, reflecting a 45.81% year-over-year growth[6] - For the first three quarters of 2021, the company achieved a revenue of RMB 748 million, representing a year-on-year growth of 46.62%[24] - The net profit attributable to shareholders for the same period was RMB 177 million, a year-on-year increase of 45.30%, with a net profit excluding non-recurring gains and losses of RMB 173 million, up 50.43%[24] - In Q3 2021, the company's revenue grew by 30.01% year-on-year, while the net profit attributable to shareholders increased by 45.81%[24] - The total profit amounted to CNY 198,044,745, up from CNY 144,528,260, reflecting a growth of 37.0%[41] - The net profit for the current period reached CNY 170,780,575, an increase of 40.3% compared to CNY 121,732,694 in the previous period[41] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,614,087,725.97, a 43.02% increase from the end of the previous year[10] - Total assets amounted to ¥2,614,087,725.97, compared to ¥1,827,787,915.29 in the previous year, indicating a growth of 43%[34] - Total liabilities increased to ¥1,029,685,128.46, up from ¥395,228,818.82, representing a 160.5% increase[34] - The company's total equity reached ¥1,584,402,597.51, compared to ¥1,432,559,096.47 in the previous year, marking an increase of 10.6%[34] Earnings and Shareholder Information - Basic and diluted earnings per share for the quarter were both ¥0.17, up 41.67% from the same period last year[10] - The basic and diluted earnings per share were both CNY 0.43, compared to CNY 0.30 in the previous period, marking a 43.3% increase[44] - The company reported a total of 7,508 common shareholders at the end of the reporting period[16] - The top shareholder, Yuan Jiandong, holds 27.69% of the shares, totaling 113,535,123 shares[16] Research and Development - Research and development expenses totaled ¥40,448,506.85 for the quarter, which is 15.02% of the revenue, indicating a strategic focus on R&D[10] - R&D investment for Q3 2021 was RMB 40.45 million, a 31.60% increase year-on-year, with total R&D investment for the first three quarters amounting to RMB 119.78 million[24] - Research and development expenses increased to ¥119,784,659.32 in the first three quarters of 2021, compared to ¥93,854,706.37 in 2020, reflecting a 27.7% rise[38] - The company submitted a new domestic patent application and obtained 9 domestic and 6 foreign patent authorizations in Q3 2021, bringing the total patents applied to 323 and authorized to 178[24] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥82,574,695.65, showing a decline of 7.21% compared to the previous year[10] - Cash flow from operating activities generated CNY 82,574,696, slightly down from CNY 88,988,250 in the previous period[50] - Cash inflow from investment activities was CNY 312,232,703, while cash outflow was CNY 971,897,817, resulting in a net cash flow of -CNY 659,665,114[50] - The company made new equity investments in Huino Biopharmaceutical Technology (Hangzhou) Co., Ltd. and BRIGHT INNOVATIVE LP during the reporting period[27] Operational Highlights - The company experienced significant growth in its main business volume, contributing to the overall increase in revenue and profit margins[14] - The sales revenue from main business activities reached RMB 642 million, a 52.87% increase compared to the same period last year[24] - The revenue from raw material drugs was RMB 608 million, with significant growth in specific products such as Micafungin Sodium, which saw a 166.52% increase in revenue[24] - The construction progress of various projects, including the Taixing raw material drug and formulation production base, reached 81.47% completion[24] Other Financial Metrics - The weighted average return on equity increased to 4.56%, up 1.15 percentage points from the previous year[10] - The company reported a decrease in employee compensation payable to ¥9,722,636.04 from ¥29,077,459.45, a reduction of 66.5%[34] - Deferred tax assets decreased to ¥12,068,807.40 from ¥18,164,179.22, a decline of 33.7%[34] - The company experienced a significant increase in sales revenue, with cash received from sales reaching CNY 642,445,103, compared to CNY 524,772,947 in the previous period, reflecting a growth of 22.4%[46]